neutrophil migration inhibitory factor

from T lymphocytes; inhibits migration of human neutrophils; characterized by electrophoresis & microassay

Also Known As:

NIF-T; neutrophil immobilizing factor

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        neutrophil migration inhibitory factor: 3
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        neutrophil migration inhibitory factor: 3
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Lymphokines: 811
      - neutrophil migration inhibitory factor: 3

Related Diseases

1.	Connective Tissue Diseases (Connective Tissue Disease) 12/01/1983 - "These studies suggest that the response of neutrophils to NIF-T may be blocked by serum, possibly as a result of immune complexes or autoantibodies found primarily in patients with connective tissue disease."
2.	Myeloid Leukemia (Leukemia, Myelocytic) 12/14/1984 - "The NIF-T was found to potently stimulate the growth of granulocyte and macrophage colonies from human bone marrow and colony formation by the KG-1 myeloid leukemia cell line. " 01/01/1982 - "Neutrophil migration inhibition factor from T lymphocytes (NIF-T): selective removal of biologic activity by human peripheral blood neutrophils, myelocytic leukemia cells, and differentiated HL-60 cells."
3.	Spondylarthropathies 12/01/1983 - "In contrast, none of 47 subjects, including healthy individuals and patients with spondylarthropathies, cancer, and active infections had a serum factor that prevented neutrophils from responding to NIF-T (P less than 0.01). "
4.	Neoplasms (Cancer) 12/01/1983 - "In contrast, none of 47 subjects, including healthy individuals and patients with spondylarthropathies, cancer, and active infections had a serum factor that prevented neutrophils from responding to NIF-T (P less than 0.01). "
5.	Infections 12/01/1983 - "In contrast, none of 47 subjects, including healthy individuals and patients with spondylarthropathies, cancer, and active infections had a serum factor that prevented neutrophils from responding to NIF-T (P less than 0.01). "

Related Drugs and Biologics

1.	Autoantibodies
2.	Antigen-Antibody Complex (Immune Complex)